المؤلفون: Gregucci, Fabiana, Spada, Sheila, Barcellos-Hoff, Mary Helen, Bhardwaj, Nina, Chan Wah Hak, Charleen, Fiorentino, Alba, Guha, Chandan, Guzman, Monica L, Harrington, Kevin, Herrera, Fernanda G, Honeychurch, Jamie, Hong, Theodore, Iturri, Lorea, Jaffee, Elisabeth, Karam, Sana D, Knott, Simon RV, Koumenis, Constantinos, Lyden, David, Marciscano, Ariel E, Melcher, Alan, Mondini, Michele, Mondino, Anna, Morris, Zachary S, Pitroda, Sean, Quezada, Sergio A, Santambrogio, Laura, Shiao, Stephen, Stagg, John, Telarovic, Irma, Timmerman, Robert, Vozenin, Marie-Catherine, Weichselbaum, Ralph, Welsh, James, Wilkins, Anna, Xu, Chris, Zappasodi, Roberta, Zou, Weiping, Bobard, Alexandre, Demaria, Sandra, Galluzzi, Lorenzo, Deutsch, Eric, Formenti, Silvia C

المصدر: Oncoimmunology. 12(1)

مصطلحات موضوعية: Humans, Neoplasms, Immunotherapy, Combined Modality Therapy, FLASH radiotherapy, dose and fractionation, immune checkpoint inhibitors, immunomodulators, lymph node sparing, tumor-associated macrophages, Immunization, Cancer, Vaccine Related, Immunology, Oncology and Carcinogenesis

الوصف: Focal radiation therapy (RT) has attracted considerable attention as a combinatorial partner for immunotherapy (IT), largely reflecting a well-defined, predictable safety profile and at least some potential for immunostimulation. However, only a few RT-IT combinations have been tested successfully in patients with cancer, highlighting the urgent need for an improved understanding of the interaction between RT and IT in both preclinical and clinical scenarios. Every year since 2016, ImmunoRad gathers experts working at the interface between RT and IT to provide a forum for education and discussion, with the ultimate goal of fostering progress in the field at both preclinical and clinical levels. Here, we summarize the key concepts and findings presented at the Sixth Annual ImmunoRad conference.

وصف الملف: application/pdf

الوصول الحر: https://escholarship.org/uc/item/29h9x11vTest

المؤلفون: Karasarides, Maria, Cogdill, Alexandria P, Robbins, Paul B, Bowden, Michaela, Burton, Elizabeth M, Butterfield, Lisa H, Cesano, Alessandra, Hammer, Christian, Haymaker, Cara L, Horak, Christine E, McGee, Heather M, Monette, Anne, Rudqvist, Nils-Petter, Spencer, Christine N, Sweis, Randy F, Vincent, Benjamin G, Wennerberg, Erik, Yuan, Jianda, Zappasodi, Roberta, Lucey, Vanessa M Hubbard, Wells, Daniel K, LaVallee, Theresa

المصدر: Cancer Immunology Research. 10(4)

مصطلحات موضوعية: Cancer, Good Health and Well Being, Antineoplastic Agents, Immunological, Humans, Immune Checkpoint Inhibitors, Neoplasms, Immunology, Oncology and Carcinogenesis, Pharmacology and Pharmaceutical Sciences

الوصف: Immune-checkpoint inhibitors (ICI), although revolutionary in improving long-term survival outcomes, are mostly effective in patients with immune-responsive tumors. Most patients with cancer either do not respond to ICIs at all or experience disease progression after an initial period of response. Treatment resistance to ICIs remains a major challenge and defines the biggest unmet medical need in oncology worldwide. In a collaborative workshop, thought leaders from academic, biopharma, and nonprofit sectors convened to outline a resistance framework to support and guide future immune-resistance research. Here, we explore the initial part of our effort by collating seminal discoveries through the lens of known biological processes. We highlight eight biological processes and refer to them as immune resistance nodes. We examine the seminal discoveries that define each immune resistance node and pose critical questions, which, if answered, would greatly expand our notion of immune resistance. Ultimately, the expansion and application of this work calls for the integration of multiomic high-dimensional analyses from patient-level data to produce a map of resistance phenotypes that can be utilized to guide effective drug development and improved patient outcomes.

وصف الملف: application/pdf

الوصول الحر: https://escholarship.org/uc/item/8dp382fmTest

المؤلفون: Bedognetti, Davide, Ceccarelli, Michele, Galluzzi, Lorenzo, Lu, Rongze, Palucka, Karolina, Samayoa, Josue, Spranger, Stefani, Warren, Sarah, Wong, Kwok-Kin, Ziv, Elad, Chowell, Diego, Coussens, Lisa M, De Carvalho, Daniel D, DeNardo, David G, Galon, Jérôme, Kaufman, Howard L, Kirchhoff, Tomas, Lotze, Michael T, Luke, Jason J, Minn, Andy J, Politi, Katerina, Shultz, Leonard D, Simon, Richard, Thórsson, Vésteinn, Weidhaas, Joanne B, Ascierto, Maria Libera, Ascierto, Paolo Antonio, Barnes, James M, Barsan, Valentin, Bommareddy, Praveen K, Bot, Adrian, Church, Sarah E, Ciliberto, Gennaro, De Maria, Andrea, Draganov, Dobrin, Ho, Winson S, McGee, Heather M, Monette, Anne, Murphy, Joseph F, Nisticò, Paola, Park, Wungki, Patel, Maulik, Quigley, Michael, Radvanyi, Laszlo, Raftopoulos, Harry, Rudqvist, Nils-Petter, Snyder, Alexandra, Sweis, Randy F, Valpione, Sara, Zappasodi, Roberta, Butterfield, Lisa H, Disis, Mary L, Fox, Bernard A, Cesano, Alessandra, Marincola, Francesco M

المصدر: Journal for ImmunoTherapy of Cancer. 7(1)

مصطلحات موضوعية: Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Genetics, Cancer, Human Genome, Underpinning research, 1.1 Normal biological development and functioning, Aetiology, 2.1 Biological and endogenous factors, Good Health and Well Being, Advisory Committees, Animals, Biomarkers, Tumor, Congresses as Topic, Disease Models, Animal, Humans, Immunotherapy, Medical Oncology, Neoplasms, Societies, Medical, Treatment Outcome, Tumor Microenvironment, Cancer immune responsiveness, Immune checkpoint inhibitor, Immune oncology, Tumor microenvironment, Tumor mutational burden, Immunogenic cell death, Biomarker, Germline molecular alterations, Somatic molecular alterations, Cancer immune phenotype, Society for Immunotherapy of Cancer (SITC) Cancer Immune Responsiveness Task Force and Working Groups, Oncology and carcinogenesis

الوصف: Tumor immunology has changed the landscape of cancer treatment. Yet, not all patients benefit as cancer immune responsiveness (CIR) remains a limitation in a considerable proportion of cases. The multifactorial determinants of CIR include the genetic makeup of the patient, the genomic instability central to cancer development, the evolutionary emergence of cancer phenotypes under the influence of immune editing, and external modifiers such as demographics, environment, treatment potency, co-morbidities and cancer-independent alterations including immune homeostasis and polymorphisms in the major and minor histocompatibility molecules, cytokines, and chemokines. Based on the premise that cancer is fundamentally a disorder of the genes arising within a cell biologic process, whose deviations from normality determine the rules of engagement with the host's response, the Society for Immunotherapy of Cancer (SITC) convened a task force of experts from various disciplines including, immunology, oncology, biophysics, structural biology, molecular and cellular biology, genetics, and bioinformatics to address the complexity of CIR from a holistic view. The task force was launched by a workshop held in San Francisco on May 14-15, 2018 aimed at two preeminent goals: 1) to identify the fundamental questions related to CIR and 2) to create an interactive community of experts that could guide scientific and research priorities by forming a logical progression supported by multiple perspectives to uncover mechanisms of CIR. This workshop was a first step toward a second meeting where the focus would be to address the actionability of some of the questions identified by working groups. In this event, five working groups aimed at defining a path to test hypotheses according to their relevance to human cancer and identifying experimental models closest to human biology, which include: 1) Germline-Genetic, 2) Somatic-Genetic and 3) Genomic-Transcriptional contributions to CIR, 4) Determinant(s) of Immunogenic Cell Death that modulate CIR, and 5) Experimental Models that best represent CIR and its conversion to an immune responsive state. This manuscript summarizes the contributions from each group and should be considered as a first milestone in the path toward a more contemporary understanding of CIR. We appreciate that this effort is far from comprehensive and that other relevant aspects related to CIR such as the microbiome, the individual's recombined T cell and B cell receptors, and the metabolic status of cancer and immune cells were not fully included. These and other important factors will be included in future activities of the taskforce. The taskforce will focus on prioritization and specific actionable approach to answer the identified questions and implementing the collaborations in the follow-up workshop, which will be held in Houston on September 4-5, 2019.

وصف الملف: application/pdf

الوصول الحر: https://escholarship.org/uc/item/9kr2t79tTest

المؤلفون: Bedognetti, Davide, Ceccarelli, Michele, Galluzzi, Lorenzo, Lu, Rongze, Palucka, Karolina, Samayoa, Josue, Spranger, Stefani, Warren, Sarah, Wong, Kwok-Kin, Ziv, Elad, Chowell, Diego, Coussens, Lisa M, De Carvalho, Daniel D, DeNardo, David G, Galon, Jérôme, Kaufman, Howard L, Kirchhoff, Tomas, Lotze, Michael T, Luke, Jason J, Minn, Andy J, Politi, Katerina, Shultz, Leonard D, Simon, Richard, Thórsson, Vésteinn, Weidhaas, Joanne B, Ascierto, Maria Libera, Ascierto, Paolo Antonio, Barnes, James M, Barsan, Valentin, Bommareddy, Praveen K, Bot, Adrian, Church, Sarah E, Ciliberto, Gennaro, De Maria, Andrea, Draganov, Dobrin, Ho, Winson S, McGee, Heather M, Monette, Anne, Murphy, Joseph F, Nisticò, Paola, Park, Wungki, Patel, Maulik, Quigley, Michael, Radvanyi, Laszlo, Raftopoulos, Harry, Rudqvist, Nils-Petter, Snyder, Alexandra, Sweis, Randy F, Valpione, Sara, Zappasodi, Roberta, Butterfield, Lisa H, Disis, Mary L, Fox, Bernard A, Cesano, Alessandra, Marincola, Francesco M

المصدر: Journal for ImmunoTherapy of Cancer. 7(1)

مصطلحات موضوعية: Biomedical and Clinical Sciences, Immunology, Cancer, Society for Immunotherapy of Cancer (SITC) Cancer Immune Responsiveness Task Force and Working Groups, Oncology and carcinogenesis

الوصف: Following publication of the original article [1], the author reported that an author name, Roberta Zappasodi, was missed in the authorship list.

وصف الملف: application/pdf

الوصول الحر: https://escholarship.org/uc/item/5tk4w9vtTest